Cargando…

Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL

The NOTCH1-MYC-CD44 axis integrates cell-intrinsic and extrinsic signaling to ensure the persistence of leukemia-initiating cells (LICs) in T-cell acute lymphoblastic leukemia (T-ALL) but a common pathway to target this circuit is poorly defined. Bromodomain-containing protein 4 (BRD4) is implicated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piya, Sujan, Yang, Yaling, Bhattacharya, Seemana, Sharma, Priyanka, Ma, Huaxian, Mu, Hong, He, Hua, Ruvolo, Vivian, Baran, Natalia, Davis, R. Eric, Jain, Abhinav K., Konopleava, Marina, Kantarjian, Hagop, Andreeff, Michael, You, M. James, Borthakur, Gautam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061299/ https://www.ncbi.nlm.nih.gov/pubmed/35173274 http://dx.doi.org/10.1038/s41375-022-01516-1

Ejemplares similares

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
por: Zhang, Weiguo, et al.
Publicado: (2022)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

P460: ERK1/2 INHIBITION OVERCOMES RESSITANCE TO BCL2 INHIBITION IN ACUTE MYELOID LEUKEMIA BY IMPACT ON MITOCHONDRIAL DYNAMICS AND FUNCTION
por: Sharma, Priyanka, et al.
Publicado: (2023)

Core binding factor acute myelogenous leukemia-2021 treatment algorithm
por: Borthakur, Gautam, et al.
Publicado: (2021)

Low Expression Of PP2A Regulatory Subunit B55α Is Associated With T308 Phosphorylation Of AKT And Shorter Complete Remission Duration In Acute Myeloid Leukemia Patients
por: Ruvolo, Peter P., et al.
Publicado: (2011)

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
por: Ruvolo, Peter P., et al.
Publicado: (2017)

Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients
por: Ruvolo, Peter P., et al.
Publicado: (2015)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells
por: Carter, Bing Z., et al.
Publicado: (2015)

Another Notch in CD44
por: Dove, Alan W.
Publicado: (2001)

Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation
por: Khoury, Joseph D., et al.
Publicado: (2020)

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up
por: Masarova, Lucia, et al.
Publicado: (2017)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Cell Death and Deubiquitinases: Perspectives in Cancer
por: Bhattacharya, Seemana, et al.
Publicado: (2014)

HAUSP, a novel deubiquitinase for Rb – MDM2 the critical regulator
por: Bhattacharya, Seemana, et al.
Publicado: (2014)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine
por: Badar, Talha, et al.
Publicado: (2015)

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
por: Masarova, Lucia, et al.
Publicado: (2017)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
por: Nguyen, Daniel, et al.
Publicado: (2023)

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia
por: Sharma, Priyanka, et al.
Publicado: (2023)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
por: Sasaki, Koji, et al.
Publicado: (2015)

Notch Ankyrin Repeat Domain Variation Influences Leukemogenesis and Myc Transactivation
por: Aster, Jon C., et al.
Publicado: (2011)

Deubiquitinase USP18 promotes the progression of pancreatic cancer via enhancing the Notch1-c-Myc axis
por: Feng, Long, et al.
Publicado: (2020)

Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases
por: Bhattacharya, Seemana, et al.
Publicado: (2018)

Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
por: Benito, Juliana, et al.
Publicado: (2011)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders
por: Ravandi, Farhad, et al.
Publicado: (2020)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Acute promyelocytic leukemia current treatment algorithms
por: Yilmaz, Musa, et al.
Publicado: (2021)

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia
por: Baran, Natalia, et al.
Publicado: (2022)

Early mortality after chemotherapy as a quality indicator—the leukemia perspective
por: Kantarjian, Hagop, et al.
Publicado: (2023)

The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas
por: Al-Khreisat, Mutaz Jamal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8la2psuulvp06midjcaspa8n42